Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAM vs PBMT for Clarithromycin-Resistant H. pylori
NCT03431688Completed
- Sponsor
- Kangdong Sacred Heart Hospital
- Start
- Oct 2018
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of metronidazole, amoxicillin, bismuth subsalicylate and tetracycline in Helicobacter pylori infection (2 arms), sponsored by Kangdong Sacred Heart Hospital. Primary endpoint: H. pylori eradication rate at 14 days. Started Oct 2018; status: completed.
02
Drugs
metronidazoleamoxicillinbismuth subsalicylatetetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03431688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03431688.